|
|
|
|
|
|
|
01.10.25 - 03:03
|
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
|
|
|
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Enanta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $65.0 million. In addition, Enanta has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
J.P. Morgan, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.
The offering is being made ...
|
|
|
|
|
|
|
30.09.25 - 22:12
|
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
|
|
|
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
J.P. Morgan, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.
The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base pro...
|
|
|
|
|
|
|
|
|
03.09.25 - 12:06
|
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. (Business Wire)
|
|
|
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
“The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since joining the Company more than two decades ago, Paul's leadership and generosity of spirit have been at the core of Enanta. Paul's dedication to the Company was complete and steadfast. He carried himself with humility, led with compassion, and inspired trust, and his relationships were authentic, rich, and fun.”
Dr. Luly added, “Paul joined Enanta in September 2003 and established the finance department, bringing critical expertise that shaped the Company's growth and success. He led Enanta's Initial Public Offering in 2013 and was instrumental in advancing the Company's early partnerships, including the strategic 2006...
|
|
|
|
|
|
|
|
|
|
|
12.05.25 - 22:03
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 (Business Wire)
|
|
|
Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025
STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025
IND Enabling Studies of KIT Inhibitor EPS-1421 Ongoing
Cash and Marketable Securities Totaling $193.4 Million at March 31, 2025, Further Strengthened by a $33.8 Million Federal Income Tax Refund Received in April 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025.
“Throughout the fiscal second quarter, Enanta remained squarely focused on executing across our virology and immunology pipeline. We are thrilled to have enrolled our target of 180 patients in RSVHR, a Phase 2 study of zelicapavir in high-ris...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
